12.06.2025 • News

Schott Pharma Invests in Sterile Cartridge Production

Schott Pharma, a drug containment and delivery solutions provider, is investing more than €100 million in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges.

Representatives posing for a symbolic start of construction.
Symbolic start of construction: L to R Dr. István Orbán, Director General of Vas County Government Office, Dominique Bauert, Head of Strategic Business Field Sterile Solutions at Schott Pharma, Péter Ágh, Hungarian State Secretary for Construction and Transport, Eva Szabó, Site Manager Lukácsháza, Torsten Derr, CEO Schott AG, Andreas Reisse, CEO Schott Pharma, István Joó, Government Commissioner and CEO Hungarian Investment Promotion Agency (HIPA), Fabian Stöcker, Head of Business Segment Drug Containment Solutions at Schott Pharma, and János Virág, Mayor of Lukácsháza bury time capsule at groundbreaking event.
© Schott Pharma/Péter Benkő

Schott Pharma has expanded its Lukácsháza site with a new facility for prefillable glass syringes, which are used for GLP-1 therapies, vaccines, and biologics. Since opening in June 2024, the site has added 120 employees, begun production, and increased capacity.

With RTU cartridges, the company is now looking to add additional manufacturing capacity for high-value solutions to the site, which has sufficient space to support the company's growth strategy. “We would like to express our sincerest gratitude to the Ministry of Foreign Affairs and Trade for its support of these two expansion projects. Lukácsháza is not only an important location for ensuring supply security to customers in the region but also makes an important contribution to Schott Pharma's global growth strategy,” says Eva Szabó, Site Manager Lukácsháza.

The company is adding a high-tech RTU cartridge manufacturing facility at its Lukácsháza site, featuring advanced equipment, automated processes, and new environmental measures. This will be the company’s second site, after St. Gallen, Switzerland, to produce sterile cartridges.

Picture of the facility.
Schott Pharma is investing more than €100 million in its site in Lukácsháza, Hungary, to expand its capacity for sterile cartridges.
© Schott Pharma

Company

Logo:

Schott Pharma


Mainz
Germany

Company contact







Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read